Ovarian cancer survival rates have stagnated in the last 20 years despite the development of novel chemotherapeutic agents. Modulators of gene expression, such as histone deacetylase (HDAC) inhibitors, are among the new agents being used in clinical trials. Predictors of sensitivity to chemotherapy have remained elusive. In this study, we show that the expression of the transcriptional corepressor C-terminal binding protein-2 (CtBP2) is elevated in human ovarian tumors. Downregulation of CtBP2 expression in ovarian cancer cell lines using short-hairpin RNA strategy suppressed the growth rate and migration of the resultant cancer cells. The knockdown cell lines also showed upregulation of HDAC activity and increased sensitivity to selected HDAC inhibitors. Conversely, forced expression of wild-type CtBP2 in the knockdown cell lines reversed HDAC activity and partially rescued cellular sensitivity to the HDAC inhibitors. We propose that CtBP2 is an ovarian cancer oncogene that regulates gene expression program by modulating HDAC activity. CtBP2 expression may be a surrogate indicator of cellular sensitivity to HDAC inhibitors.
INTRODUCTION
Ovarian cancer remains the deadliest gynecologic malignancy in the United States. It is estimated that B21 550 new cases of ovarian cancer were diagnosed in 2009 in the United States with 14 600 deaths reported. 1 Survival rates have stagnated in the last 20 years despite the development of novel chemotherapeutic agents. Predictors of sensitivity to chemotherapy have remained elusive, further complicating treatment optimization in patients, who commonly present with advanced disease.
Tumor antigens are produced in cancer cells and trigger an immune response in hosts. The identification of tumor antigens has been a subject of ongoing research, as they are useful in identifying tumor cells and are potential targets for novel therapies. The C-terminal binding protein-2 (CtBP2) was identified as a tumor antigen in epithelial ovarian cancer using a reverse capture antibody array. 2 We sought to further characterize this protein and determine its role in oncogenesis.
Human CtBP2 protein 3 is homologous to human CtBP1 protein, a 48-kDa cellular phosphoprotein that binds to the C-terminal region of the human adenovirus E1A proteins. 4 CtBP family proteins are conserved transcriptional corepressors 5 that have crucial roles during development and oncogenesis. 6, 7 They also have specific functions in epithelial gene regulation and programmed cell death. 8, 9 As transcriptional co-repressors, CtBP proteins interact with and regulate the activity of more than 30 different vertebrate transcriptional factors, many of which are involved in oncogenic cell signaling pathways. 10, 11 The mechanism of transcription repression includes the recruitment of chromatin modifiers including histone deacetylases (HDACs) and histone methyltransferases. 6, 10 CtBP-mediated modification of histones can be counteracted by the HDAC inhibitor trichostatin A (TSA). 12 HDACs remove acetyl-groups from histones and alter chromatin structure and gene transcription. 13 HDAC inhibitors have gained increasing amounts of attention as potential chemotherapeutic targets. 14, 15 Various HDAC inhibitors, including suberoylanilide hydroxamic acid and TSA, have been reported to exhibit antitumor activities against hematologic, breast and bladder malignancies. 16 Suberoylanilide hydroxamic acid is currently being used in phase II clinical trials to treat recurrent ovarian cancer.
Even though CtBP1 and CtBP2 share very high sequence homology, there are some intrinsic differences between them. CtBP1 is both cytoplasmic and nuclear, with its subcellular localization regulated by sumoylation, phosphorylation and binding to a PDZ protein. 17 In contrast, CtBP2 is exclusively nuclear, and its amino acid sequence lacks a C-terminal PDZbinding motif. The CtBP2 sequence has a unique N-terminal domain that confers a dominant nuclear localization and provides Lys residues for acetylation by the nuclear acetylase p300. 18 Recent studies have also suggested the dual activator and repressor roles of CtBP2 in transcriptional regulation. 6, 19 While Ctbp1 mutant mice are viable and fertile, Ctbp2-null mice show defects in axial patterning and die by E10.5 because of aberrant extraembryonic development. 20 The goals of our study included the investigation of the expression pattern of CtBP2 in epithelial ovarian cancer and the potential role of CtBP2 in oncogenic properties and drug responses of ovarian cancer cells. Intriguingly, our studies have shown the specific function of CtBP2 in conferring the sensitivity of ovarian cancer cells to HDAC inhibitors.
RESULTS

CtBP2 expression in ovarian epithelial cancers and relationship with survival
In our previous study, autoantibody that targets CtBP2 was identified in ovarian cancer patients. 2 To investigate the expression pattern of the tumor antigen CtBP2 in ovarian tissues, we have performed immunohistochemistry using a monoclonal CtBP2-specific antibody on 103 paraffin-embedded ovarian tissues samples. Strong immunoreactivity with a high mean weighted score of 4.77 (borderline tumors) and 5.49 (invasive tumors) was found in 83% of ovarian epithelial tumors, which showed a significant difference (P-value o0.001) when compared with normal and benign ovarian tissues that had a mean score of 0.33 and 1.15, respectively (Table 1 ). There were no significant differences of staining among subtypes of ovarian tumors (P-value ¼ 0.879). Examples of normal ovarian tissue, borderline tumors and invasive tumors stained for CtBP2 are shown in Figure 1a . The majority of the staining was in the nuclei of tumor cells. No staining was observed in the stromal cells. When CtBP2 expression in the invasive ovarian tumors with survival data was analyzed, the overall survival of patients with positive CtBP2 expression was found to be poorer ( Figure 1b ) compared with those patients with negative CtBP2 expression (P-value ¼ 0.05), based on the Kaplan-Meier survival estimation. In the Cox proportional hazard regression analysis (Table 1) , a significant difference in overall survival between patients with positive and negative CtBP2 expression was found (P-value ¼ 0.017). The estimated hazard ratio for overall survival of patients with positive CtBP2 expression as compared with the negative CtBP2 expression was 9.813 (95% confidence interval: 1.50 to 64.37), with the adjustment for CA125 value and tumor stage.
Western blotting showed an increase in CtBP2 expression in seventeen human ovarian cancer cell lines when compared with normal human ovarian surface epithelial cells (Figure 2a ).
Functional analysis of ovarian cancer cell lines with CtBP2 knockdown To investigate the function of CtBP2 in ovarian cancer cells, CtBP2 expression was successfully knocked down in two ovarian cancer cell lines, SKOV3 and MCAS, using two short-hairpin RNA (shRNA) constructs (Figure 2b ). Ovarian cancer cells harboring shRNA constructs 2 and 3 demonstrated reduced expression of CtBP2 by 475%. The expression of CtBP1 was not affected by the presence of shRNA constructs (data not shown). Both SKOV3 and MCAS control and knockdown cell lines were employed for the analysis of CtBP2 function and derivatives of both cell lines showed similar results.
Cellular proliferation assays showed reduced proliferation rate of knockdown cell lines when compared with controls ( Figure 3a) . Cell-extracellular matrix adhesion assays showed that the knockdown cell lines have significantly reduced capacity to adhere to extracellular matrix proteins collagen I and collagen IV, and modest reduction of adhesion to laminin (Figure 3b) . In a transwell migration assay, the knockdown cell lines also demonstrated reduced migration rate relative to control shRNA cell lines (Figure 3c ). Supplementary Figure S1 shows the differences of number of stained cells that migrated through the transwell membrane.
As CtBP family proteins are involved in Wnt signaling, 11, 19 we tested the b-catenin activity of the cell lines using a luciferase reporter gene with upstream binding elements for bcatenin/T-cell factor (TCF) complex. Similar to the findings by Hamada et al., 21 the knockdown cell lines demonstrated significantly increased b-catenin activity (Figure 3d ), suggesting that expression of CtBP2 can downregulate Wnt signaling target genes.
CtBP2 regulates HDAC activity and affects cellular sensitivity to HDAC inhibitors The corepressor complex of CtBP2 mediates coordinated histone modification by deacetylation and methylation of histones through interactions of several factors including HDACs. 6, 10 As many of the pharmacological inhibitors of HDACs are effective antineoplastic agents against leukemias and solid tumors, 16 we asked the question whether the response of ovarian cancer cell lines to HDAC inhibitors changes with differential expression of CtBP2. In vitro cytotoxicity assays of MCAS control and knockdown cell lines to a panel of HDAC inhibitors currently in clinical and preclinical trials showed enhanced sensitivity of the CtBP2 knockdown cell lines to most of the HDAC inhibitors compared with the control cell line (Figure 4 ). The cell line harboring knockdown construct 3 was in general more sensitive to all of the inhibitors, which might be due to other side effects of the construct. It is also noted that in the treatment with MGCD0103 and valproic acid, the differences between the control and knockdown cell lines are significant only in the very high doses. Supplementary Figure S2 shows that the SKOV3 panel demonstrated similar response to the same and other HDAC inhibitors. In comparison, the knockdown cell line harboring construct shRNA2 did not show big differences in the response to the antitumor agent carboplatin (Figure 4f ), indicating that the sensitivity of CtBP2 knockdown cells to HDAC inhibitors is not due to the triggering of a common survival or death pathway that responds univerally to all kinds of antineoplastic agents.
To demonstrate that CtBP2 expression has a causative role in the sensitivity of CtBP2 knockdown cell lines to HDAC inhibitors, we reintroduced a full-length wild-type CtBP2 complementry DNA (cDNA) expression construct into the knockdown cells and compared the sensitivity of the resultant cells in association with CtBP2 expression. As the SKOV3 knockdown cell lines harbored already a luciferase construct, which would hinder clonal selection after transfection, we have only conducted the reintroduction of CtBP2 into the MCAS knockdown cell line that harbored the shRNA construct 2. Western blot analysis of two CtBP2 cDNA transfectants and the control cell lines in Figure 5a confirmed Abbreviations: CI, confidence interval; CtBP2, C-terminal binding protein-2.
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To account for the changes of the TSA sensitivity, we have determined the HDAC activity of the cell lines using a universal HDAC assay kit. As shown in Figure 5c , the shRNA construct 2-harboring MCAS cell line showed HDAC activity level that was 33% higher than that of the control shRNA-harboring cell line. In the transfectants of shRNA2-harboring MCAS cell lines, the vector control showed similar level of HDAC activity as the parental line, whereas two CtBP2 transfectants showed reduced levels of HDAC activities (19 and 13%, respectively) relative to the parental shRNA2 line (Figure 5c ). Hence, HDAC activities of the cell lines showed inverse relationship with their responses to HDAC inhibitors. To further evaluate whether there are changes in activity of specific HDAC classes, we employed two substrates to perform HDAC assays. The substrate MAZ1600 is kinetically more specific for class I HDACs (HDAC1, HDAC2, HDAC3) and HDAC6, whereas the substrate MAZ1675 is kinetically favorable for the evaluation of class IIa HDACs (HDAC4, HDAC5, HDAC7 and HDAC9) and HDAC8. As shown in Figure 5d , the knockdown shRNA2 cell line showed elevated activities to both the substrates (50% to MAZ1600 and 26% to MAZ1675), whereas both CtBP2 transfectants showed reduced levels of activity to both the substrates. The results suggest that the activity of both classes of HDACs might be affected by the cellular levels of CtBP2.
DISCUSSION
Oncogenesis is a multi-step process that involves both genetic and epigenetic events. Transcription factor complexes are master regulators of cell state during development and oncogenesis. Many of these transcription factor complexes are formed by sequence-specific DNA binding factors in association with chromatin-modifying enzymes for gene transcriptional activation or repression. 15 The corepressor complex of CtBP2 mediates coordinated histone modification by deacetylation and methylation of histones through interactions of several factors including HDACs. 6, 10 Our immunohistochemical study has shown the overexpression of CtBP2 in ovarian tumor cells and its expression is associated with poor survival (Figure 1 and Table 1 ). CtBP2 is likely an oncogene that epigenetically alters gene transcription and contributes to neoplasia.
Ovarian cancer cells with CtBP2 knockdown exhibit a multitude of dysfunctions that include reduced cell proliferation, cellextracellular matrix adhesion and cell migration capacity. Hence, the CtBP2 transcription program is responsible for cell growth and cell migration and invasion, properties that are pivotal to oncogenic transformation and metastasis. 22 Dysregulation of b-catenin levels and constitutive activation of b-catenin/TCFregulated gene expression occur in many human cancers. bcatenin is stabilized upon Wnt stimulation and moves into the nucleus, where it binds to members of the TCF transcription factor family and the formed complexes modulate transcription. 23 TCF mutations and alterations in the APC and b-catenin may contribute to oncogenesis. 11, 23, 24 However, CtBP proteins have been reported to interact with APC protein and suppress the expression of Wnt signaling target genes. 11, 21 Consistent with those reports, our b-catenin assay also showed that b-catenin activity was increased in the CtBP2 knockdown cell lines. Whether suppression of Wnt signaling bears any significance to CtBP2 function in ovarian cancer awaits further investigation.
CtBP2 complex is a chromatin remodeling complex that involves HDACs, a group of enzymes that have gained increasing amounts of attention as potential chemotherapeutic targets. 14, 15 Our CtBP2 knockdown cell lines showed increased sensitivity to all HDAC inhibitors tested, with the exception of MGCD0103 and valproic acid. In the cytotoxicity assay with carboplatin, the cancer cell line harboring shRNA2 did not show differences in response, indicating that the CtBP2-dependent drug sensitivity is restricted to HDAC inhibitors. The cancer cell line harboring shRNA3 did show some significantly increased sensitivity to carboplatin, which we believe was due to side effects of the construct, as this line showed significant drop in growth rate and was in general hypersensitive to other stress treatments. Furthermore, reintroduction of wild-type CtBP2 partially rescued the cancer cells to cytotoxicity mediated by HDAC inhibitors (Figure 5) , strongly supporting the notion that cytotoxicity to HDAC inhibitors is in accordance with the level of CtBP2 expression. Our HDAC assays have shown that cellular HDAC activity was elevated in the knockdown cell lines and reversed in the CtBP2 cDNA transfectants. Hence, cellular sensitivity to HDAC inhibitors is proportional to the HDAC activity, which is inversely proportional to the CtBP2 expression level. Both class I and class II HDACs are believed to be recruited to CtBP either directly or via other complex proteins. 6, 25 It is not known, however, whether HDAC activity can be interferred by CtBP complex. As cellular response to HDAC inhibitors is of clinical relevance, further mechanistic studies on potential modulation of HDAC activity by CtBP2 are warranted. The results of class-specific HDAC assays have suggested that the activity of both class I and class IIa enzymes were elevated in the CtBP2 knockdown cells. Valproic acid is unique in that it has less activity against class II HDACs. 26 Similarly, MGCD0103 is also a class I HDAC-specific inhibitor. 27 The less drastic effects of both agents on the knockdown cell lines suggest that isoformselectivity may account for the differences of efficacy of HDAC inhibitors, and that the nonselective HDAC inhibitors may be more desirable in treating human cancers.
In conclusion, we have shown overexpression of CtBP2 protein in ovarian tumors and its function in regulating cell growth, cell migration and b-catenin activity. We are the first to show that CtBP2 knockdown cell lines have increased sensitivity specific to HDAC inhibitors, suggesting that the expression of CtBP2 might be a marker for response to these chemotherapeutic agents in the clinical setting. It will be of great interest to investigate which of the HDACs are active in ovarian tumors and how nonselective inhibitors are more effective in treating ovarian cancer. As CtBP2 is dominantly overexpressed in ovarian tumors, it is of profound importance to design adjuvant therapy that can overcome CtBP2 expression in ovarian tumors.
MATERIALS AND METHODS
Ovarian clinical samples and ovarian cell lines
All patient-derived biologic specimens were collected and archived under protocols approved by the Human Subjects Committee of the Brigham and Women's Hospital, Boston, Massachusetts. Archived formalin-fixed, paraffin-embedded normal, benign and cancerous ovarian tissues were collected from women undergoing surgery at the Brigham and Women's Hospital for a diagnosis of primary ovarian cancer or from control subjects ; (e) valproic acid; and (f ) carboplatin, a non-HDAC inhibitor. The P-values for differences between the knockdown cell lines and the control are indicated. In (d) and (e), the doses with significant differences are marked with an *, which represents Po0.05.
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L Barroilhet et al who were undergoing the procedure of hysterectomy or oophorectomy for benign gynecologic indications. Samples were collected with written informed consent from patients and confirmed histologically by pathologists. Cases were staged according to the International Federation of Gynecology and Obstetrics system. The normal human ovarian surface epithelial cells and the ovarian cancer cell lines have been described previously. 28 Normal human ovarian surface epithelial cells were collected by scraping the ovarian surface of the control subjects who were undergoing hysterectomy or oophorectomy for benign diseases. Longterm human ovarian surface epithelial cells were immortalized by a HPV E6/E7 gene introduction. All ovarian cell lines were maintained in a mixture of medium 199 and MCDB105 medium (1:1) (Sigma, St Louis, MO, USA) supplemented with 10% fetal calf serum (Invitrogen, Carlsbad, CA, USA).
Immunohistochemistry
Paraffin-embedded ovarian tissue blocks were sectioned at a thickness of 7 mm and mounted on Superfrost Plus microscopic slides (Fisher Scientific, Pittsburgh, PA, USA), and dried at 50 1C for at least 3 h. Deparaffinization was performed using xylene and rehydration with a graded ethanol series. Antigen retrieval was performed in a pressure-cooker in antigenunmasking solution (Vector Laboratories, Burlingame, CA, USA). Endogenous peroxidases were blocked using 0.3% H 2 0 2 in methanol for 20 min. The sections were then blocked with normal horse serum for 20 min and were subsequently incubated overnight with anti-CtBP2 (monoclonal, 1:80 dilution; BD Biosciences, San Jose, CA, USA) as the primary antibody. After incubation, the reaction was visualized using Vectastain Elite ABC Kit with diaminobenzidine chromogen as a substrate (Vector Laboratories). Sections were counterstained lightly with hematoxylin and mounted. Immunohistochemical results were evaluated by two trained investigators. CtBP2 staining was graded semi-quantitatively by considering the percentage and intensity of the staining. A histological score was obtained from each sample, which ranged from 0 (no immunoreaction) to 9
(maximum immunoreactivity). The score was obtained by multiplying the intensity of the stain (0 for no stain, 3 for intense stain) by the percentage of the epithelial tissue that stained positive (0 for no stain, 3 for 100% of the epithelium staining positive).
Lentiviral Infection and DNA transfection
Mission lentiviral CtBP2-targeting and non-target control shRNA transduction particles were purchased from Sigma-Aldrich (St Louis, MO, USA). The RNAi Consortium numbers for the shRNAs 1-5 are N0000013743, N0000013744, N0000013745, N0000013746 and N0000013747, respectively. For the effective knockdown shRNA2 and 3, they target the positions 1021-1042 and 1144-1165, respectively, of the NM_001329 CtBP2 transcript sequence. 1 Â 10 5 MCAS and SKOV3 ovarian cancer cells growing in complete medium were infected with 5 Â 10 5 transduction particles in the presence of 8 mg/ml hexadimethrine bromide (SigmaAldrich) and incubated overnight at 37 1C and 5% CO 2 . On the third day, the medium was replaced with complete medium containing 2 mg/ml puromycin and changed every 3 days for 2 weeks. Knockdown of CtBP2 expression in the resultant cell lines was confirmed by western blot analysis. To rescue the CtBP2 expression in the knockdown cell lines, fulllength CtBP2 cDNA expression construct and empty vector purchased from OriGene Technologies (Rockville, MD, USA) were transfected separately into the CtBP2 shRNA clone-2 MCAS cell line using Lipofectamine 2000 transfection reagent (Invitrogen Corp.). The transfected cells were selected using complete medium containing 500 mg/ml G418 (Invitrogen Corp.) and the CtBP2 expression in the transfected cells was confirmed by Western blot analysis. It was noted that the reappearance of CtBP2 expression was not stable. The selected positive clones reverted to loss of CtBP2 expression with time, especially after thawing from frozen stocks. The experimental results described here were performed in the early stage of clone selection during which the CtBP2 expression was rescued. We have later transfected the CtBP2 cDNA expression construct 
Western blot
Total cell lysates were prepared from growing cells using lysis buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS) supplemented with PhosStop phosphatase inhibitor cocktail and complete protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN, USA). Protein concentration was measured with a MicroBCA protein assay kit (ThermoScientific, Rockford, IL, USA). Ten microgram of total cell lysates of the cell lines were resolved by SDSpolyacrylamide gel electrophoresis and transferred to a polyvinylidene fluoride membrane using a SEMI-DRY transfer cell (Bio-Rad Laboratories, Hercules, CA, USA). After blocking with 5% nonfat dry milk in 1 Â Tris Buffer Saline Tween20 buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% Tween-20) at room temperature for 1 h, the membrane was incubated with the primary antibody (anti-CtBP2, BD Biosciences) at 4 1C overnight then washed at room temperature. The bound antibody was detected by the anti-mouse secondary antibodies conjugated with horseradish peroxidase (Pierce Biotechnology, Rockford, IL, USA) and a supersignal west pico kit (Pierce Biotechnology).
Cell growth, adhesion and migration assays Cell proliferation was determined by seeding 3 Â 10 4 cells to 35-mm culture dishes and allowed to grow to different time points. At each time point, the number of cells in three culture dishes were counted and averaged for each cell line. Adhesion to components of the extracellular matrix was evaluated using CytoMatrix cell adhesion strips (Millipore, Billerica, MA, USA) and performed according to the instructions of the manufacturer. Cell migration was evaluated in transwell inserts with 8 mm pore-sized polyethylene terephthalate membranes (BD Biosciences) coated with 10 mg/ml collagen (Sigma-Aldrich) overnight. The following day, 1 Â 10 5 /ml cells in serum-free medium containing 0.05% bovine serum albumin were added to the inserts. The inserts were then placed in the wells of a companion plate and incubated with complete medium containing 10% fetal bovine serum in the lower chamber. After 24 h of incubation, the cells in the inserts were scraped with cotton swaps. The membranes were excised from the inserts and counterstained with DiffQuik Stain Set (Dade Behring Inc., Newark, DE, USA). The cells that migrated through the membrane were counted in four random fields. Each experiment was repeated twice and average values ± s.e.m are presented.
b-catenin activity assay b-catenin activity was measured using a luciferase reporter assay. The cells were transfected with a TOP-FLASH luciferase reporter plasmid (Addgene, Cambridge, MA, USA) that contains multimers of b-catenin/TCF-binding sequences upstream of the firefly luciferase reporter gene. A Renilla luciferase-encoding plasmid pRL-CMV (Promega, Madison, WI, USA) was included in the transfection as internal control. Another transfection with a FOP-FLASH (Addgene) plasmid that harbors mutant b-catenin/TCF-binding sites, together with pRL-CMV plasmid, was performed to serve as negative control. Preparation of cell lysates and luciferase assay was performed using the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's protocol. Luminescence was measured using a TD-20/ 20 luminometer (Turner Designs, Sunnyvale, CA, USA). The firefly luciferase activities of the cell lines were normalized by the respective Renilla luciferase activities. Each transfection was performed in triplicates and repeated twice. The results are reported as means ± s.e.'s.
Cytotoxicity assay
Cellular sensitivity to HDAC inhibitors and carboplatin (Sigma-Aldrich) was measured using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays. The following HDAC inhibitors were tested: belinostat, vorinostat, MGCD0103 (Selleck, Pittsburgh, PA, USA), splitomicin, M344 (Biovision, Mountainview, CA, USA), TSA and valproic acid (Sigma-Aldrich).
Cell suspensions (7 Â 10 4 cells/ml) were seeded in 100 ml of medium per well in 96-well plates. After overnight incubation, 100 ml of medium with serial dilutions of each HDAC inhibitor were added for 48 h. Twenty microliter of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide solution (5 mg/ml in PBS, Sigma-Aldrich) was added to each well and incubated for 4 h. Medium was aspirated and 100 ml of combined solubilization solutions, 10% SDS in 0.01N HCl, and 0.1N HCl in 2-propanol (1:1), was added to each well. Absorbance at 562 nm was determined on an EL Â 800 absorbance microplate reader (Bio-Tek, Winooski, VT, USA). Each drug assay was performed in triplicates and repeated twice.
HDAC activity assays
Universal HDAC activity was measured using a colorimetric HDAC activity assay kit (BioVision). Fifty microgram of diluted nuclear extracts, prepared using nuclear and cytoplasmic extraction kit (Pierce Biotechnology, Rockford, IL, USA), were incubated with HDAC colorimetric substrate in 1 Â HDAC assay buffer at 37 1C for 1 h. Reactions were stopped by adding 10 ml of lysine developer and mixed for 30 min. Samples were read at 405 nm on an EL Â 800 absorbance microplate reader (Bio-Tek). Classspecific HDAC assays were performed as described. 29 Briefly, nuclear extracts were incubated with a series of doses of fluorophore-conjugated substrates in assay buffer (50 mM HEPES, 100 mM KCl, 0.001% (v/v) Tween-20, 0.05% (w/v) bovine serum albumin, 200 mM tris(2-carboxyethyl) phosphine, pH 7.4) and followed for fluorogenic release of 7-amino-4-methylcoumarin from substrates upon deacetylase and trypsin enzymatic activity. Fluorescence measurements were obtained every 5 min using a multilabel plate reader (Envision, Perkin-Elmer, Waltham, MA, USA). Data were analyzed for the mid-linear range of fluorescence over time and plotted versus substrate concentrations. In these assays, the substrate MAZ1600 was kinetically more specific for HDAC1, HDAC2, HDAC3 and HDAC6, whereas the substrate MAZ1675 was kinetically favorable for HDAC4, HDAC5, HDAC7, HDAC8 and HDAC9. As a negative control, a reaction was performed in the presence of 10 mM of TSA. The assays were performed in duplicates and repeated twice.
Statistical Analysis
All calculations were performed with MINITAB statistical software (Minitab, State College, PA, USA) unless otherwise indicated. ANOVA was used to compare the mean immunohistochemistry scores between benign and malignant paraffin sections and between different tumor histologies. Significance of the test was considered at the 5% level (that is, P-value p0.05). For the survival analysis, the length of overall survival was defined from the date of operation to the date of the patient's death (uncensored) or the date of last visit (censored). We defined the low and high CtBP2 expression groups using the cutoff score of 3.5. The choice of cutoff score was based on the ability to group cases with significant differences in overall survival. Overall survivals of patients with positive and negative CtBP2 expression were estimated using the Kaplan-Meier method, and compared with a log-rank test. The impact of CtBP2 expression on patient survival was further studied with the inclusion of potential clinical risk factors, using the Cox proportional hazards regression model. The variables applied for adjustment in the multivariate analysis included tumor grade, stage of disease, histologic type, CA125 values, optimal or suboptimal debulking and patient's age. Patient's age was treated as a continuous variable, while tumor grade, stage of disease and histologic type were analyzed as categorical variables. Grade 1 was grouped as the reference group to identify the risk of death of grades 2 and 3 cases. Stage 1 and 2 cases were grouped as the reference group to evaluate the risk of death of the combination of stage 3 and 4 cases. Histologic type was classified as either serous or nonserous. With the multivariate Cox proportional hazards analysis, the variables were entered into the model using a backward stepwise Wald-test process. The impact of CtBP2 expression on patient survival was determined by examining the relative hazard ratios with respect to the positive/negative CtBP2 expression groups in the final model. The significance of estimated hazard ratios was tested using the Wald test. The Cox regression analysis was performed using the SPSS 17.0 statistical software. (SPSS, Inc., Chicago, IL, USA).
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